Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients

British Journal of Clinical Pharmacology

Volumn 45, Issue 4, 1998, Pages 377-380

  Harder, Sebastian ^a   Thürmann, Petra A ^a   Ungethüm, Wolfram ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MERCK KGAA   (Germany)

Author keywords

ACE inhibitor; Imidapril; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAPRIL; PLACEBO;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG METABOLISM; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; STEADY STATE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AREA UNDER CURVE; FEMALE; HALF-LIFE; HUMANS; HYPERTENSION; IMIDAZOLES; IMIDAZOLIDINES; MALE; MIDDLE AGED; PLACEBOS;

EID: 0031884418     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00694.x     Document Type: Article

References (12)

1. Demolis P, Annane D, Duhaze P, Giudicelli JF. Systemic, regional and cerebral hemodynamic effects of a new angiotensin converting enzyme inhibitor, imidapril, in healthy volunteers. Fundam Clin Pharmacol 1994; 8: 80-89.
2. Vandenburg M, Mackay EM, Dews I, Pullan T, Brugier S. Dose finding studies with imidapril - new ACE-inhibitor. Br J Clin Pharmacol 1994; 37: 265-272.
3. Pinto YM, vanVeldhuisen DJ, Tjon-Ka-Jie RT, Rooks G, Netzer T, Lie KI. Dose-finding study of imidapril, a novel ACE-inhibitor, in patients with stable chronic heart failure. Eur J Clin Pharmacol 1996; 50: 265-268.
4. Tagawa K, Mizobe M, Noda K. A saturable tissue-angiotensin-I-converting enzyme binding model for the pharmacokinetic analysis of imidapril, a new ACE-inhibitor, and its active metabolite in human. Biol Pharmaceutical Bull 1995; 18: 64-69.
5. Harder S, Thürmann PA. Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. Br J Clin Pharmacol 1997; 43: 475-480.
6. Francis RJ, Brown AN, Kler L, et al. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to converting enzyme inhibition: Development of a mathematical model. J Cardiovasc Pharmacol 1987; 9: 32-38.
7. Donnelly R, Meredith PA, Elliott HL, Reid JL. Kinetic-dynamic relations and individual responses to enalapril. Hypertension 1990; 15: 301-309.
8. Elliott HL, Macdonald NJ, Meredtith PA, Reid JL. Dose responses and pharmacokinetics for the angiotensin converting enzyme inhibitor quinapril. Clin Pharmacol Ther 1992; 51: 260-265.
9. Brocknieier D. Tight binding of ramiprilat to ACE. Consequences for pharmacokinetic and pharmacodynamic measurements. Int J Clin Pharmacol Ther 1995; 33: 631-638.
10. Meredith PA, Elliott HL, Reid JL, Francis RJ. The pharmacokinetics and angiotensin converting enzyme inhibition dynamics of cilazapril in essential hypertension. Br J Clin Pharmacol 1989; 27: 263S-266S.
11. Louis WJ, Workman BS, Conway EL, et al. Single dose and steady state pharmacokinetics and pharmacodynamics of perindopril in hypertensive subjects. J Cardiovasc Pharmacol 1992; 20: 505-511.
12. Jackson B, Johnston CI, Angiotensin converting enzyme during acute and chronic enalapril therapy in essential hypertension. Clin Exp Pharmacol Physiol 1984; 11: 355-360.